Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

Author(s): Muenst S, Schaerli AR, Gao F, Däster S, Trella E, et al.


Recent studies in multiple epithelial cancers have shown that the inhibitory receptor programmed cell death 1 (PD-1) is expressed on tumor-infiltrating lymphocytes and/or programmed death ligand 1 (PD-L1) is expressed on tumor cells, suggesting that antitumor immunity may be modulated by the PD-1/PD-L1 signaling pathway. In addition, phase 1 clinical trials with monoclonal antibodies targeting PD-1 or PD-L1 have shown promising results in several human cancers. The purpose of this study was to investigate the impact of PD-L1 expression in human breast cancer specimens. We conducted an immunohistochemistry study using a tissue microarray encompassing 650 evaluable formalin-fixed breast cancer cases with detailed clinical annotation and outcomes data. PD-L1 was expressed in 152 (23.4 %) of the 650 breast cancer specimens. Expression was significantly associated with age, tumor size, AJCC primary tumor classification, tumor grade, lymph node status, absence of ER expression, and high Ki-67 expression. In univariate analysis, PD-L1 expression was associated with a significantly worse OS. In multivariate analysis, PD-L1 expression remained an independent negative prognostic factor for OS. In subset analyses, expression of PD-L1 was associated with significantly worse OS in the luminal B HER2− subtype, the luminal B HER2+ subtype, the HER2 subtype, and the basal-like subtype. This is the first study to demonstrate that PD-L1 expression is an independent negative prognostic factor in human breast cancer. This finding has important implications for the application of antibody therapies targeting the PD-1/PD-L1 signaling pathway in this disease.

Similar Articles

Trends in incidence of small cell lung cancer and all lung cancer

Author(s): Riaz SP, Lüchtenborg M, Coupland VH, Spicer J, Peake MD, et al.

Current small cell lung cancer treatment in China

Author(s): Shi Y, Xing P, Fan Y, Zhang X, Hu C, et al.

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1pathway

Author(s): Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

Author(s): Schmidt LH, Kümmel A, Görlich D, Mohr M, Bröckling S, et al.

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Author(s): Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, et al.

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Author(s): Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, et al.

In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas

Author(s): Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, et al.